https://www.selleckchem.com/products/mst-312.html
Tau in Alzheimer's disease (AD) is assessed via cerebrospinal fluid (CSF) and Positron emission tomography (PET). Novel methods to detect phosphorylated tau (pTau) in blood have been recently developed. We aim to investigate agreement of tau status as determined by [ F]MK6240 tau-PET, plasma pTau181 and pTau231. We assessed cognitively unimpaired young, cognitively unimpaired, mild cognitive impairment and AD individuals with [ F]MK6240, plasma pTau181, pTau 231, [ F]AZD4694 amyloid-PET and MRI. A subset underwent CSF assessment. We con
Like
Comment
Share
